FY2025 EPS Estimates for Esperion Therapeutics, Inc. Decreased by Zacks Research (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at Zacks Research decreased their FY2025 earnings per share estimates for Esperion Therapeutics in a note issued to investors on Monday, April 29th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn $0.02 per share for the year, down from their previous estimate of $0.05. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the same period in the previous year, the company posted ($0.76) EPS.

A number of other research firms have also weighed in on ESPR. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Monday, March 25th. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, April 10th. Finally, Bank of America cut Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Trading Down 1.0 %

Shares of ESPR stock opened at $1.97 on Tuesday. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40. The company has a market capitalization of $373.12 million, a price-to-earnings ratio of -0.93 and a beta of 0.84. The firm has a 50-day moving average price of $2.37 and a 200 day moving average price of $2.02.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Esperion Therapeutics by 120.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock valued at $405,000 after acquiring an additional 225,767 shares in the last quarter. GSA Capital Partners LLP raised its position in Esperion Therapeutics by 159.1% in the third quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock valued at $1,094,000 after purchasing an additional 685,733 shares during the period. PSI Advisors LLC lifted its stake in shares of Esperion Therapeutics by 161.5% during the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 10,500 shares in the last quarter. Simplicity Solutions LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter worth about $30,000. Finally, Pinnacle Associates Ltd. boosted its position in shares of Esperion Therapeutics by 15.7% in the third quarter. Pinnacle Associates Ltd. now owns 289,123 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 39,285 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.